Search | Clinical Trials Finder

Conditions: Antibody-mediated Rejection, Allosensitization
Interventions: Isatuximab, bone marrow biopsy; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Transplantation
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Durham, North Carolina • Research Triangle Park, North Carolina

Conditions: Lung Transplantation Rejection
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Durham, North Carolina • Research Triangle Park, North Carolina

Conditions: Rejection Chronic Renal
Interventions: Belumosudil 200 mg QD, Placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Transplantation
Interventions: fostamatinib, Placebo; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Stanford, California • Baltimore, Maryland • Salt Lake City, Utah + 1 more

Conditions: Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection, Lung Transplant; Complications, Lung Transplant Failure and Rejection, Chronic Lung Allograft Dysfunction
Interventions: Liposomal Cyclosporine A, Standard of Care; Drug
Lead sponsor: Zambon SpA; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity, Chronic Rejection of Lung Transplant
Interventions: Liposomal aerosol cyclosporine, standard immune suppression, oral; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Rejection of Lung Transplant
Interventions: Lung transplant recipient without MRI imaging, Lung transplant recipient with MRI imaging; Diagnostic Test · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2038
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions: Portable Dynamic Digital Radiography (DDR); Diagnostic Test
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Transplant Rejection
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lung Transplant Reject, Bronchiolitis Obliterans
Interventions: Mesenchymal stem cell 0.5, Mesenchymal stem cell 1.0; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Graft Rejection, Lung Disease
Interventions: Non-interventional; Other
Lead sponsor: XDx; Industry
Eligibility: Not listed
Enrollment: 2,044 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Lung Transplant Failure and Rejection
Interventions: Allosure; Diagnostic Test
Lead sponsor: Pablo Sanchez; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gastroesophageal Reflux
Interventions: esophagogastroduodenoscopy, Standard GER questionnaire (RDQ), Scintigraphic evaluation of solid gastric emptying, Twenty-four hour ambulatory pH testing, Esophageal manometry testing; Procedure · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Interventions: Not listed
Lead sponsor: CareDx; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more

Conditions: Lung Transplant Failure and Rejection, CLAD, Bronchiolitis Obliterans, Extracorporeal Photopheresis
Interventions: Not listed
Lead sponsor: Brian Keller; Other
Eligibility: 7 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Boston, Massachusetts • Columbus, Ohio

Conditions: Lung Transplant Rejection
Interventions: macitentan, placebo (for macitentan); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Transplant, Chronic Allograft Rejection
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Durham, North Carolina • Research Triangle Park, North Carolina

Conditions: Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions: LAM-001, Placebo; Drug
Lead sponsor: Steven Hays, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Antibody Mediated Rejection of Lung Transplant
Interventions: Siltuximab, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • Saint Lake City, Utah

Conditions: Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions: Placebo, EZ-2053, EZ-2053 5mg/kg; Biological
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Bronchiolitis Obliterans, Lung Transplant Rejection
Interventions: High Resolution Computed Tomography scan; Radiation
Lead sponsor: FLUIDDA nv; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York • Gibson, Pennsylvania

Conditions: Delayed Graft Function, Acute Graft Rejection
Interventions: azathioprine, sirolimus; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Isatuximab in Lung Transplant Recipients

Can Immune Parameters Predict Acute and Chronic Rejection in Lung Recipients?

Prospective Lung Transplant Database for Genetic Research

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

Longitudinal Study of Cell Free DNA in Lung Transplant

Mesenchymal Stem Cell Therapy for Lung Rejection

Lung Allograft Rejection Gene Expression Observational (LARGO) Study

Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation

GI Reflux in Lung Transplant and Its Relationship to Chronic Rejection

AlloSure Lung Assessment and Metagenomics Outcomes Study

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

Mechanisms of Lung Allograft Rejection

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

Transplant Optimization Using Functional Imaging

Comparison of Sirolimus and Azathioprine in Lung Transplantation